30 July 2026
Fezolinetant and elinzanetant now frame nonhormonal care
Fezolinetant (Veozah; Astellas Pharma US, Inc) became the first FDA-approved NK3 receptor antagonist for moderate-to-severe VMS.
The full briefing is in the app.
30 July 2026
Fezolinetant (Veozah; Astellas Pharma US, Inc) became the first FDA-approved NK3 receptor antagonist for moderate-to-severe VMS.
The full briefing is in the app.